News

Novo Nordisk bags drug delivery platform
Enlarge image

BusinessDenmark

Novo Nordisk bags drug delivery platform

03.05.2012 - Denmark’s Novo Nordisk has exclusively licensed Caisson's heparosan-based drug delivery to develop compounds of its drug pipeline.

Oklahoma City/Austin/Baegsvard – With the exclusive license deal, Novo Nordisk has secured a key platform to extend the life cycle of its existing drugs by simply attaching them to bio-inert sugar polymers, which cannot be degraded extra-cellularly. Under the terms of the agreement, Caisson Biotech LLC, a wholly owned subsidiary of Heparinex, L.L.C, will receive an undisclosed upfront payment from the Danish drugmaker plus fees for contract research and manufacturing. In addition, Caisson will be eligible to receive milestone payments upon achievement of certain predefined clinical, regulatory and commercial targets, plus royalties on the global sales of the therapeutic products developed under the agreement, representing a total deal value of more than $100m. 

Caisson’s drug delivery technology, who was invented by the firm’s CSO Dr. Paul DeAngelis at the University of Oklahoma, utilises heparosan, a naturally occurring sugar polymer that is stable and inert in the bloodstream, but is biodegradable inside cells for the purpose of cloaking, enlarging and/or protecting drug cargo. Heparosan can be customised with respect to polymer size and conjugation chemistry, thus increasing product half-life, reducing immunogenicity, and increasing stability. 

In contrast to PEGylation, heparosanylation shows no toxicity. Additionally, Caisson Biotech claims higher and faster water solubility, longer excretion half life and its larger flexibility concerning usage to different drug types and delivery systems.

http://www.european-biotechnology-news.com/news/news/2012-02/novo-nordisk-bags-drug-delivery-platform-for-100m.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

BusinessSwedenFrance

02.06.2015 After disappointing Phase III results for immunotherapy tasquinimod and the subsequent discontinuation of the prostrate cancer drug, Swedish Active Biotech is now severely downsizing its operations.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

EPOSwitzerland

30.05.2015 Pharma giant Roche has out-licensed its anaemia drug Mircera to fellow Swiss healthcare company Galenica.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)26.20 SEK19.09%
  • PROTHENA PLC (IE)42.69 USD6.86%
  • GW PHARMACEUTICALS (UK)657.00 GBP5.65%

FLOP

  • ANTISOMA (UK)1.00 GBP-35.48%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ACTIVE BIOTECH (S)9.45 SEK-10.85%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • GALAPAGOS (B)51.79 EUR37.8%
  • FLAMEL TECHNOLOGIES (F)19.55 USD36.3%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)26.20 SEK-48.4%
  • CYTOS (CH)0.59 CHF-41.6%
  • ANTISOMA (UK)1.00 GBP-35.5%

TOP

  • CELLECTIS (F)38.88 EUR518.1%
  • WILEX (D)4.11 EUR470.8%
  • ADOCIA (F)67.61 EUR440.4%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-81.8%
  • ACTIVE BIOTECH (S)9.45 SEK-72.0%
  • THROMBOGENICS (B)5.33 EUR-70.0%

No liability assumed, Date: 02.06.2015